Gyre Research Development from 2010 to 2026
| GYRE Stock | 8.02 0.20 2.56% |
Research Development | First Reported 2005-03-31 | Previous Quarter 3.4 M | Current Value 2.4 M | Quarterly Volatility 5.9 M |
Check Gyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gyre Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 127.7 M, Gross Profit of 123 M or Other Operating Expenses of 59.9 M, as well as many indicators such as Price To Sales Ratio of 8.32, Dividend Yield of 0.17 or PTB Ratio of 19.45. Gyre financial statements analysis is a perfect complement when working with Gyre Therapeutics Valuation or Volatility modules.
Gyre | Research Development | Build AI portfolio with Gyre Stock |
Analyzing Gyre Therapeutics's Research Development over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research Development has evolved provides context for assessing Gyre Therapeutics's current valuation and future prospects.
Latest Gyre Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Gyre Therapeutics over the last few years. It is Gyre Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gyre Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Gyre Research Development Regression Statistics
| Arithmetic Mean | 29,028,754 | |
| Geometric Mean | 21,396,619 | |
| Coefficient Of Variation | 85.16 | |
| Mean Deviation | 20,044,409 | |
| Median | 16,686,000 | |
| Standard Deviation | 24,719,532 | |
| Sample Variance | 611.1T | |
| Range | 89.3M | |
| R-Value | (0.30) | |
| Mean Square Error | 593.2T | |
| R-Squared | 0.09 | |
| Significance | 0.24 | |
| Slope | (1,468,304) | |
| Total Sum of Squares | 9776.9T |
Gyre Research Development History
About Gyre Therapeutics Financial Statements
Gyre Therapeutics stakeholders use historical fundamental indicators, such as Gyre Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Although Gyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Gyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 13.8 M | 13.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:Check out the analysis of Gyre Therapeutics Correlation against competitors. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Biotechnology sector continue expanding? Could Gyre diversify its offerings? Factors like these will boost the valuation of Gyre Therapeutics. Market participants price Gyre higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Gyre Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.662 | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.199 | Return On Assets |
Understanding Gyre Therapeutics requires distinguishing between market price and book value, where the latter reflects Gyre's accounting equity. The concept of intrinsic value - what Gyre Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Gyre Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Gyre Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.